Get the Stockscreener App
3.60
1.91%
-0.07
After Hours:
3.60
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Altimmune Inc stock is traded at $3.60, with a volume of 1.78M.
It is down -1.91% in the last 24 hours and down -24.37% over the past month.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
See More
Previous Close:
$3.67
Open:
$3.65
24h Volume:
1.78M
Relative Volume:
0.33
Market Cap:
$291.99M
Revenue:
$409.00K
Net Income/Loss:
$-101.35M
P/E Ratio:
-2.1951
EPS:
-1.64
Net Cash Flow:
$-71.49M
1W Performance:
-1.37%
1M Performance:
-24.37%
6M Performance:
-47.90%
1Y Performance:
-39.14%
1-Day Range:
$3.535
$3.65
1-Week Range:
$3.535
$3.77
52-Week Range:
$2.90
$11.16
Altimmune Inc Stock (ALT) Company Profile
Name
Altimmune Inc
Sector
Industry
Phone
(240) 654-1450
Address
910 CLOPPER ROAD, GAITHERSBURG, MD
Compare ALT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
3.60 | 297.66M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
385.65 | 96.11B | 11.42B | 3.64B | -1.26B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.13 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
428.14 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.15 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
298.52 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Sell |
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Jan-08-25 | Initiated | Stifel | Buy |
| Nov-12-24 | Initiated | UBS | Buy |
| Apr-29-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-24-24 | Initiated | Goldman | Neutral |
| Mar-22-23 | Downgrade | Goldman | Buy → Neutral |
| Dec-01-22 | Initiated | Goldman | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-02-21 | Initiated | H.C. Wainwright | Buy |
| Feb-11-21 | Initiated | Guggenheim | Buy |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Nov-12-20 | Reiterated | B. Riley Securities | Buy |
| Sep-25-20 | Initiated | B. Riley FBR | Buy |
| Aug-14-20 | Initiated | Evercore ISI | Outperform |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jul-28-20 | Initiated | JMP Securities | Mkt Outperform |
| Feb-24-20 | Resumed | ROTH Capital | Buy |
| Jul-19-19 | Initiated | ROTH Capital | Buy |
| Oct-09-17 | Initiated | Piper Jaffray | Overweight |
View All
Altimmune Inc Stock (ALT) Latest News
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
Investor Alert: Deadline Approaching to Join Altimmune, Inc. (ALT) Class ActionContact Levi & Korsinsky - Newsfile
Altimmune, Inc. Investors: Please contact the Portnoy Law - GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - Morningstar
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc.ALT - PR Newswire
Altimmune Inc. stock momentum explainedPrice Forecast Based on AI Analysis - Newser
Order flow analysis tools used on Altimmune Inc.Entry Confirmation Using Short-Term Forecasting - Newser
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Altimmune, Inc. Securities and Sets a Lead Plaintiff Deadline of October 6, 2025 - Business Upturn
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors - GlobeNewswire
What makes Altimmune Inc. stock attractive to long term investorsFree Triple Return Setup with Risk Control - Newser
Altimmune reports Q2 2025 financial results on August 12. - AInvest
Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025 | ALT Stock News - GuruFocus
Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025 - The Manila Times
Why Altimmune Inc. stock attracts strong analyst attentionFree Weekly Return Pick Forecast Reports - Newser
Clinical-Stage Biotech Altimmune Sets Q2 2025 Earnings DateKey Details for Investors - Stock Titan
Analyzing recovery setups for Altimmune Inc. investorsFree Access to Smart Investment Tips - Newser
Levi & Korsinsky Investigates Altimmune, Inc. (ALT) Over Potential Securities Fraud Allegations - ACCESS Newswire
Market reaction to Altimmune Inc.’s recent newsTechnical Insight Guide for Safer Trades - Newser
Published on: 2025-08-04 04:35:56 - Newser
Should I hold or sell Altimmune Inc. stock in 2025Free Market Dynamics Reports - Jammu Links News
What are Altimmune Inc. company’s key revenue driversExtraordinary profit generation - Jammu Links News
Does Altimmune Inc. stock perform well during market downturnsRapid portfolio appreciation - Jammu Links News
What makes Altimmune Inc. stock price move sharplyCapitalize on high-growth stocks early - Jammu Links News
Is Altimmune Inc. a good long term investmentDynamic profit opportunities - Jammu Links News
Protect Your Investment: Contact Levi & Korsinsky About the Altimmune, Inc. (ALT) Investigation - ACCESS Newswire
What catalysts could drive Altimmune Inc. stock higher in 2025Unlock powerful trading signals and alerts - Jammu Links News
How volatile is Altimmune Inc. stock compared to the marketCapitalize on momentum-driven stocks - jammulinksnews.com
How strong is Altimmune Inc. company’s balance sheetDiscover stocks with superior performance - Jammu Links News
Is Altimmune Inc. stock overvalued or undervaluedAchieve superior returns through strategic trading - Jammu Links News
Shareholders Alert: Investigation Into Altimmune, Inc. (ALT)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
How Altimmune Inc. stock performs during market volatilityReal Time Stock Movement and Alerts - Newser
Applying chart zones and confluence areas to Altimmune Inc.High Reward Picks with Tight Risk Control - Newser
What institutional investors are buying Altimmune Inc. stockFree Stock Data Feed Backed By Experts - Jammu Links News
Altimmune, Inc. (ALT) Stock Analysis: Exploring The 376.96% Potential Upside - DirectorsTalk Interviews
Is Altimmune Inc. reversing from oversold territorySafe Momentum Strategy With Trend Analysis - Newser
What is the risk reward ratio of investing in Altimmune Inc. stockExpert Picks Insights For Fast Growth - Jammu Links News
Altimmune Bets Big On Next-Gen Obesity And Liver Drugs - Finimize
Levi & Korsinsky Launches Fraud Investigation on Behalf of Altimmune, Inc. (ALT) Shareholders - ACCESS Newswire
Published on: 2025-07-31 05:27:57 - Newser
How to use a screener to detect Altimmune Inc. breakoutsTechnical Reversal Pattern Summary and Tracker - Newser
Altimmune Inc. stock daily chart insightsGrowth Based Investment Plan Guidance Highlighted - metal.it
How sentiment analysis helps forecast Altimmune Inc.Chart Pattern Recognition for Profit Timing - Newser
Regression analysis insights on Altimmune Inc. performanceWeekly Chart-Based Forecast for Traders - Newser
Is Altimmune Inc. stock reversal real or fakeEntry Opportunity Screener with Confirmation - Newser
Altimmune, Inc. Securities Lawsuit Investigation - Claim Depot
Real Time Data Flags Unusual Activity in Altimmune Inc.Oversold Bounce Stock Play Ideas Gain Attention - beatles.ru
ALT Investor Notice: Levi & Korsinsky Investigates Altimmune, Inc. For Securities Law Violations - ACCESS Newswire
Altimmune, Inc. (ALT) Under Investigation for Potential Securities Law ViolationsContact Levi & Korsinsky Today - ACCESS Newswire
What are analysts’ price targets for Altimmune Inc. in the next 12 monthsHigh-impact investment strategies - jammulinksnews.com
Altimmune Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingWatchlist Winner Update - Newser
Altimmune Inc Stock (ALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.10%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):